Lung cancer is the deadliest cancer worldwide, exhibiting the highest incidence rate among all cancer types. Poor outcomes often characterize this cancer as it is commonly diagnosed in advanced stages due to its unspecific symptoms. After diagnosis, the therapeutic choice is a crucial stage that profoundly affects patients’ survival. Treatment choices for lung cancer must be made carefully, acknowledging the histological type and genetic characteristics of the tumor. Non-small cell lung cancer, the most common and complex type, has a high mutational burden, making next-generation sequencing (NGS) essential for identifying specific mutations and guiding treatment. With several approved targeted therapies already available, this approach highlights the critical role of personalized medicine in lung cancer care. Despite the current therapeutic pipeline, research trying to develop new tailored drugs considering individual patient characteristics has evolved over the years. This article aims to outline the current therapeutic approach for each type of lung cancer and present the latest insights into emerging therapies, highlighting the role of personalized medicine in enhancing treatment outcomes and improving patients’ quality of life.
肺癌是全球致死率最高的癌症，在所有癌症类型中发病率居首位。由于症状缺乏特异性，该疾病常在晚期才被确诊，导致预后普遍不佳。确诊后，治疗选择成为深刻影响患者生存的关键阶段。肺癌治疗方案需审慎制定，必须充分考虑肿瘤的组织学类型和遗传特征。非小细胞肺癌作为最常见且最复杂的类型，具有高突变负荷特征，这使得新一代测序技术成为识别特定突变、指导治疗决策的关键手段。随着多种靶向疗法相继获批临床应用，个体化医疗在肺癌治疗中的核心地位日益凸显。尽管现有治疗体系不断完善，多年来针对患者个体特征研发新型定制药物的探索持续深入。本文旨在系统阐述当前各类型肺癌的治疗策略，并聚焦新兴疗法的最新进展，重点探讨个体化医疗在提升治疗效果、改善患者生活质量方面的重要作用。
肿瘤(癌症)患者之家